Salubrinal 2 mg | 99.97%
TargetMol
Salubrinal, a phosphatases (PP1) inhibitor(IC50=1.7 μM), exhibits function on the eukaryotic translation initiation factor 2 subunit (eIF2α).
More Information Supplier PageSalubrinal
Search Results
Salubrinal 50 mg | 99.97%
TargetMol
Salubrinal, a phosphatases (PP1) inhibitor(IC50=1.7 μM), exhibits function on the eukaryotic translation initiation factor 2 subunit (eIF2α).
More Information Supplier PageSalubrinal
Salubrinal 5 mg | 99.97%
TargetMol
Salubrinal, a phosphatases (PP1) inhibitor(IC50=1.7 μM), exhibits function on the eukaryotic translation initiation factor 2 subunit (eIF2α).
More Information Supplier PageSalubrinal
ALK-IN-1 100 mg | Purity Not Available
TargetMol
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
More Information Supplier PageALK-IN-1
ALK-IN-1 10 mg | Purity Not Available
TargetMol
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
More Information Supplier PageALK-IN-1
Olverembatinib 5 mg | 99.29%
TargetMol
Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
More Information Supplier PageOlverembatinib
Olverembatinib 2 mg | 99.29%
TargetMol
Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
More Information Supplier PageOlverembatinib
Olverembatinib 10 mg | 99.29%
TargetMol
Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
More Information Supplier PageOlverembatinib
ALK-IN-1 5 mg | Purity Not Available
TargetMol
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
More Information Supplier PageALK-IN-1
ALK-IN-1 50 mg | Purity Not Available
TargetMol
ALK-IN-1 (AP26113) is a potent ALK inhibitor with IC50 of 0.62 nM in a cell-free assay, demonstrated ability overcome Crizotinib resistance mediated by a L1196M mutation. Phase 2.
More Information Supplier PageALK-IN-1